Stock ALLOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Allos Therapeutics, Inc.

Equities

US0197771019

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Allos Therapeutics, Inc.

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.
BU
Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN(R) in Europe
PU
Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
BU
Allos Therapeutics, Inc. : Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
BU
Allos Therapeutics, Inc. : Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
BU
Allos Therapeutics, Inc. : Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012
BU
Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN(R) in PTCL at the European Medicines Agency
PU
Allos Therapeutics, Inc. : Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN(R) and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
PU
Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Allos Therapeutics, Inc.